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Abbreviations 
 
ALK1   Activin-like kinase 1 
ECM   Extra Cellular Matrix 
EXT   Exostosin family 
EXT1   Exostosin 1 
EXT2   Exostosin 2 
EXTL3   Exostosin Like Glycosyltransferase 3 
GAGs   Glycosaminoglycans 
Glc-NAc  N-acetylglucosamine 
Glc-NS   N-sulfo glucosamine  
Glc-UA    D-glucuronic acid 
HA   Hyaluronan 
hAoSMC  human Aortic Smooth Muscle Cells 
HAS2   Hyaluronan Synthase 2 
HAS3   Hyaluronan Synthase 3 
HASs   Hyaluronan Synthases 
HE   Heparin 
HS   Heparan sulfate 
HSPGs    Heparan sulfate proteoglycans 
HYAL   Hyaluronidase 
HUVEC   Human Umbilical Vein Endothelial Cells 
IdoA    Iduronic acid 
LOX1   Lectin-like oxidized low-density lipoprotein receptor-1 
LDL   Low density lipoprotein 
LDLR   Low density lipoprotein receptor 
NDST1   N-deacetylase/N-sulfotransferase 1 
N-LDL   normal-low density lipoprotein  
NO   Nitric oxide 
NOS1   Nitric oxide synthase 1 
NOS2   Nitric oxide synthase 2 
NOS3   Nitric oxide synthase 3 
NOSs   Nitric oxide synthases 
OX-LDL   oxidised-low density lipoprotein 
PCSK9   Proprotein convertase subtilisin/kexin type 9 
PGs   Proteoglycans 
siRNA   short interference RNA 
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SDC1   Syndecan 1 
SDC2   Syndecan 2 
SDC3   Syndecan 3 
SDC4   Syndecan 4 
SDCs   Syndecans 
SMC    Smooth muscle cell (s) 
TNFα   Tumor Necrosis Factor alpha 
  
7 
 
1 – SUMMARY 
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Since cardiovascular diseases are the first cause of death in developed world, there is 
an increasing interest in studying the molecular bases of these diseases as well as 
identifying novel therapies to prevent or control such pathologies.  
Atherosclerosis is a chronic inflammatory disease of medium and large size arteries. 
Endothelial dysfunctions and low-density lipoprotein (LDL) accumulation in the tunica 
intima are the main factors which contribute to extracellular matrix (ECM) modification 
during atherosclerotic plaque formation. Nevertheless, the exact mechanisms 
underlying the impaired vascular structure remain unresolved. 
 
Given these considerations, this project is focused on the glycocalyx and ECM 
characterization in vascular cells. We want to elucidate the role of hyaluronan (HA) and 
syndecans, two of the major components of glycocalyx, in endothelial cells after 
treating with TNFα in order to mimic a pro-inflammatory stimulus. This issue can be 
useful to understand the prevention potentials of ECM components as well as their 
negative impact on the onset of the disease. Another aspect examined is the action of 
PCSK9, a novel therapeutic target for LDL-lowering, on HA metabolism and LDL 
receptors both in endothelial cells and smooth muscle cells (SMC) because very few 
information is available about PCSK9 role in the ECM and cholesterol metabolism 
regulation in vascular cells. 
 
We used human umbilical vein cells (HUVEC) treated with TNFα finding a modulation 
of HA synthase (HASs) transcripts. In particular, among the three HAS isoenzymes, we 
found an increase of HAS2 and a decrease of HAS3 expression levels. Accordingly, HA 
in the pericellular coat slightly increase suggesting that in vivo HA could be modified in 
the glycocalyx altering its adhesive properties controlling immune cells and platelets 
recruitment. 
TNFα stimulation also affects syndecan4 (SDC4) core protein expression as well as its 
glycosaminoglycans (GAGs) chain composed mainly by heparan sulfate (HS). Moreover, 
the SDC4 overexpression after the pro-inflammatory stimulation correlates with a 
reduction in HUVEC permeability measured by FITC-dextran diffusion through a cell 
coated Transwell system. As many functions of SDC4 depends on its GAGs chain, we 
found an upregulation of the critical enzymes involved in the synthesis of HS (i.e. EXT1, 
EXT2 and NDST1). Since NDST1 modifies GAG chain catalyzing both the N-deacetylation 
and the N-sulfation of glucosamine residue, we measured by HPLC the N-sulfation of 
HS residues and we found an increased amount. As N-sulfation levels in HS are involved 
in the inhibition of thrombus formation, we used HS extracted form HUVEC membrane 
and conditioned medium for platelets assays that revealed a decrease of platelets 
spreading. 
These data suggest that, during endothelial inflammation, the alteration of HA 
synthesis, SDC4 expression and its GAGs chains chemical composition can influence the 
platelets recruitments and, further, could promote the LDL accumulation during the 
onset of atherosclerosis. 
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In addition, we focused our attention on PCSK9, a critical hematic factor involved in the 
homeostasis of the cholesterol-LDL regulating LDL receptor (LDLR). This enzyme is 
mainly synthetized in liver and, to verify whether vascular cells could contribute to 
PCSK9 expression, we treated HUVEC and human aortic smooth muscle cells (hAoSMC) 
with several factors finding that only in hAoSMC treated with normal (N-LDL) and 
oxidized LDL (OX-LDL) PCSK9 mRNA levels and protein secretion were reduced.  
As PCSK9 can be present in different plasmatic concentrations in healthy patients and 
hypercholesterolemic subjects, we examined whether it can have a role in LDL 
receptors expression in vascular cells. Our results indicated that PCSK9 did not 
influence neither LDLR nor the ALK1 (that is implicated in N-LDL transcytosis) both in 
HUVEC and in hAoSMC. Interestingly, LOX1, one of the main OX-LDL scavenger 
receptor, is not affected by PCSK9 in hAoSMC but is dramatically reduced in HUVEC. 
As an alteration in HA metabolism is involved in vessel thickening, we evaluated HA 
biosynthetic enzymes and receptor after PCSK9 treatments. We found that the 
expression of HASs and CD44 (the main HA receptor) are differently altered depending 
on the vascular cell type. In particular, in HUVEC and hAoSMC we measured a decrease 
of HAS3 whereas HAS2 and CD44 expression decreased specifically in hAoSMC. 
These data indicate that PCSK9 could have a vaso-protective role regulating molecules 
involved in HA homeostasis. Therefore, the therapeutic inhibition of PCSK9 can have a 
positive function in liver lowering LDL but a different effect on vascular system. 
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2 – RIASSUNTO 
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Poiché le malattie cardiovascolari sono la prima causa di morte nel mondo in via di 
sviluppo, vi è un crescente interesse nello studio delle basi molecolari di queste 
malattie, nonché nell'identificazione di nuove terapie per prevenire o controllare tali 
patologie. 
L'aterosclerosi è una malattia infiammatoria cronica di arterie di media e grande 
dimensione. Le disfunzioni endoteliali e l'accumulo di lipoproteine a bassa densità (LDL) 
nella tunica intima sono i principali fattori che contribuiscono alla modificazione della 
matrice extracellulare (ECM) durante la formazione della placca aterosclerotica. 
Tuttavia, i meccanismi esatti alla base della struttura vascolare compromessa 
rimangono irrisolti. 
 
Date queste considerazioni, questo progetto si focalizza sulla caratterizzazione del 
glicocalice e della ECM nelle cellule vascolari. Vogliamo chiarire il ruolo dell’acido 
ialuronico (HA) e dei sindecani, componenti principali del glicocalice, nelle cellule 
endoteliali dopo il trattamento con TNFα al fine di mimare uno stimolo pro-
infiammatorio. Questo punto può essere utile per comprendere i potenziali di 
prevenzione dei componenti della ECM e il loro impatto negativo sull'insorgenza della 
malattia. Un ulteriore aspetto esaminato è l'azione di PCSK9, un nuovo bersaglio 
terapeutico per l'abbassamento dell'LDL. Ci siamo focalizzati sul metabolismo dell'HA e 
sui recettori per le LDL sia nelle cellule endoteliali che nelle cellule muscolari lisce (SMC) 
perché sono disponibili pochissime informazioni sul ruolo di PCSK9 nell'ECM e nella 
regolazione del metabolismo del colesterolo nelle cellule vascolari. 
 
Abbiamo utilizzato cellule umane di vena ombelicale (HUVEC) trattate con TNFα 
trovando una modulazione delle trascrizioni di HA sintasi (HASs). In particolare, tra i tre 
isoenzimi di HAS, abbiamo riscontrato un aumento di HAS2 e una diminuzione dei livelli 
di espressione di HAS3. Di conseguenza, l'HA nel rivestimento pericellulare aumenta 
leggermente, suggerendo che l'HA in vivo potrebbe essere modificato nel glicocalice 
alterando le sue proprietà adesive e controllando il reclutamento di cellule del sistema 
immunitario e di piastrine. 
La stimolazione del TNFα influenza anche l'espressione del core proteico del syndecan4 
(SDC4) e la sua catena di glicosamminoglicani (GAG) composta principalmente da 
eparan solfato (HS). Inoltre, la sovra-espressione di SDC4 dopo la stimolazione pro-
infiammatoria si correla con una riduzione della permeabilità delle HUVEC misurata 
mediante diffusione di FITC-destrano attraverso un sistema Transwell rivestito di 
cellule. Molte funzioni di SDC4 dipendono dalla sua catena fatta da GAG e nel nostro 
studio abbiamo trovato una sovra-regolazione degli enzimi critici coinvolti nella sintesi 
di HS (cioè EXT1, EXT2 e NDST1). NDST1 modifica la catena di GAG catalizzando sia la N-
deacetilazione che la N-solfatazione dei residui di glucosammina. Pertanto, abbiamo 
misurato mediante HPLC la N-solfatazione dei residui di HS che è risultata aumentata 
in modo significativo. Poiché i livelli di N-solfatazione in HS sono coinvolti nell'inibizione 
della formazione di trombi, abbiamo usato HS estratti dalla membrana di HUVEC e dal 
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loro terreno condizionato per analisi piastriniche che hanno rivelato una diminuzione 
nello spreading delle piastrine. 
Questi dati suggeriscono che, durante l'infiammazione endoteliale, l'alterazione della 
sintesi di HA, dell'espressione di SDC4 e della composizione chimica della sua catena di 
GAG possono influenzare il reclutamento di piastrine e, inoltre, potrebbero 
promuovere l'accumulo di LDL durante l'insorgenza dell’aterosclerosi. 
 
In aggiunta, abbiamo focalizzato la nostra attenzione su PCSK9, un critico fattore 
ematico coinvolto nell'omeostasi del colesterolo-LDL che regola il recettore per le LDL 
(LDLR). Questo enzima è principalmente sintetizzato nel fegato e, per verificare se le 
cellule vascolari potrebbero contribuire all'espressione di PCSK9, abbiamo trattato 
HUVEC e cellule muscolari lisce dell'aorta umana (hAoSMC) con diversi fattori che ci 
hanno fatto scoprire che solo in hAoSMC trattate con LDL normali (N-LDL) e ossidate 
(OX-LDL) i livelli di mRNA e la secrezione proteica di PCSK9 sono ridotti. 
Poiché PCSK9 può essere presente in diverse concentrazioni plasmatiche in pazienti 
sani e in soggetti ipercolesterolemici, abbiamo esaminato se possa avere un ruolo 
nell'espressione dei recettori per le LDL nelle cellule vascolari. I nostri risultati hanno 
indicato che PCSK9 non ha influenzato né LDLR né ALK1 (che è implicato nella transcitosi 
delle N-LDL) sia in HUVEC che in hAoSMC. È interessante notare che LOX1, uno dei 
principali recettori scavenger per le OX-LDL, non è influenzato da PCSK9 in hAoSMC, ma 
è drasticamente ridotto in HUVEC. 
Poiché un'alterazione del metabolismo dell'HA è coinvolta nell'ispessimento dei vasi, 
abbiamo valutato gli enzimi e i recettori biosintetici dell'HA dopo i trattamenti con 
PCSK9. Abbiamo trovato che l'espressione di HAS e CD44 (il principale recettore per 
l’HA) sono alterati in modo diverso a seconda del tipo di cellule vascolari. In particolare, 
in HUVEC e hAoSMC abbiamo misurato una diminuzione di HAS3 mentre l'espressione 
di HAS2 e CD44 è diminuita specificatamente in hAoSMC. 
Questi dati indicano che PCSK9 potrebbe avere un ruolo vaso-protettivo che regola le 
molecole coinvolte nell'omeostasi dell'HA. Pertanto, l'inibizione terapeutica di PCSK9 
può avere una funzione positiva nel ridurre il colesterolo LDL ma un diverso effetto sul 
sistema vascolare. 
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3.1 Atherosclerosis 
 
Atherosclerosis is considered a chronic inflammation disease of the arterial vessel.  
This pathology is characterised by a significative thickening of the intima in which 
cholesterol and lipids accumulation are covered by a rigid extracellular matrix cap 
forming the so-called atheromatous plaque that protrudes within the vessel lumen 
(Boyle et al. 1997). 
The lesions occur principally in large and medium-size elastic and muscular arteries 
(Ross 1999). Inside the arterial tree, branching points and bifurcations are the more 
susceptible regions because in these vessel portions the blood flow is disturbed. 
Turbulences and pressure oscillations can lead to the loss of the atheroprotective effect 
of the endothelial layer (Gimbrone et al. 2000).  
The lesion can manifest precociously in human life even during childhood (Lusis 2000). 
The initial and soft lesion can be reversible, but the formation of a mature and complex 
plaque in adult age usually lead to thrombosis and the most devastating consequences 
are myocardial infarction, when the thrombus occurs in the coronary arteries, or 
stroke, when it occurs in the cerebral arteries (Falk 2006)(E. Karangelis et al. 2012).  
Atherosclerosis is the first cause of mortality in the developed world, together with the 
other cardiovascular diseases. To date, the exact causes of atherosclerosis are 
unknown. Nevertheless, multiple factors are associated with an increased risk of 
atherosclerotic cardiovascular disease that are summarized in Table 1. Most of them 
are modifiable factors indicating that healthy diet, exercising and not smoking are the 
major preventing factors. Therefore, the treatment of established disease include 
medical therapies in combination with changes in lifestyle (Rafieian-Kopaei et al. 2014). 
 
 
Modifiable Non-modifiable 
Hyperlipidaemia 
Hypertension 
Diabetes 
Abdominal obesity 
Smoking 
Unhealthy diet and nutrition 
Physical inactivity 
Age 
Gender and ethnicity 
Genetic disposition 
 
Table 1. Atherosclerosis risk factors. 
 
 
3.1.1 Atherosclerosis possible causes  
 
Two hypotheses are emerged about the onset and progression of atherosclerosis. 
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The “response of injury” hypothesis by Ross proposed that some of atherosclerosis risk 
factors lead to qualitative changes of endothelium as change in permeability and 
increase of adhesion molecules expression that attract leucocytes. This endothelial 
response to injury represents the first phase of an inflammatory response that leads to 
atherosclerosis onset (Ross 1999). Recent postulates based on experimental studies on 
atherosclerosis in animals designate that the apparition of endothelial dysfunctions 
triggered by irritative stimuli as dyslipidemia, hypertension and cigarette smoking, is an 
early atherogenic event (Maiolino et al. 2013). 
On the other hand, Williams and Tabas proposed the “response to lipoprotein 
retention” hypothesis, which affirms that atherogenic low density lipoproteins (LDL) 
are retained in the intima by binding to extracellular proteoglycans (Nakashima et al. 
2007) that have a high affinity for lipoproteins (Rafieian-Kopaei et al. 2014). In addition, 
the LDL-proteoglycan complex are more susceptible to oxidation leading to their 
uptake by macrophages that became foam cells and contribute to plaque formation 
and inflammatory cells reclutament (Chait and Wight 2000). 
From these postulates it is evident that atherosclerosis is a complex disease in which 
endothelial dysfunction, inflammatory process and lipoprotein retention are in a close 
relation and contribute to lesion development. The scheme in Figure 1 reports this 
correlation.  
 
 
 
Figure 1 – Relations between the atherosclerosis triggering factors 
 
 
3.1.2 Role of vascular cells in atherosclerosis process 
 
The vessel wall is composed by the endothelium formed by a single layer of endothelial 
cells, the tunica intima with smooth muscle cells (SMC), and the tunica adventitia with 
fibroblasts and SMC. These layers are surrounded by perivascular adipose tissue. Every 
component is involved in atherosclerosis progression: endothelium dysfunction is 
considered one of the triggering factors of atherosclerosis development, SMC 
migration and proliferation are implicated in atherosclerosis progression, and 
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fibroblasts from adventitia and adipocytes from perivascular adipose tissue contribute 
to atherosclerosis nourishment (Wang et al. 2017).  
The first visible lesions in the development of atherosclerosis plaques are the fatty 
streaks along the luminal surface of the artery. They appear as an irregular yellow-white 
discoloration consisting of lipids from lipoprotein of cholesterol and aggregates of foam 
cells, which are lipoprotein-loaded macrophages located in the intima (Ross 1999). 
During atherosclerotic process, an endothelial injury as shear stress or oxidative stress 
induces in endothelial cell a compensatory response. Endothelial cells start to produce 
cytokine, chemokines and adhesion molecules (i.e. VCAM-1) causing monocytes and 
lymphocytes-T migration and adhesion (Ross 1995) (Figure 2).  
The injury also induces change in endothelial permeability that increases the passage 
of lipoproteins to the sub-endothelium and allows the monocytes infiltration in the 
intima tunica that differentiate into macrophages (Wang et al. 2017). This leads to the 
early atheroma formation: cytokine stimulated SMC move from media to intima and, 
after a phenotypically switch to secreting type cells, start to produce extracellular 
matrix (ECM) components causing a massive deposition of hyaluronan (HA) in the 
lesion site  that enhances the recruitment of myeloid cells as T cells and platelets (Ross 
1999)(Viola et al. 2013). 
Moreover, in the arterial wall, lipoprotein particles (especially low-density lipoprotein 
or LDL) undergo oxidation (become OX-LDL) and they are internalized by macrophages 
and SMC. These cells retain the lipid components of LDL and becoming more lipid-laden 
form the so called "foam cells" (Chistiakov et al. 2017). The accumulation of OX-LDL can 
lead to foam cell apoptosis or necrosis (Leiva et al. 2015). 
The advanced lesion becomes stable when the SMC production of collagen and elastin 
lead to the building of a fibrous cap over the lipid core forming by aggregates of lipids 
and cells debris (Leiva et al. 2015). The consequent increase of intima thickening leads 
to a lumen diameter reduction.  
As showing in Figure 3, the growing plaque can be stabilized, or it can break (unstable 
plaque) causing the extravasation of the necrotic core of the plaque and the exposition 
of the sub-endothelium. This causes platelets activation and aggregation leading to a 
thrombus formation. Usually, the thrombosis can result in stroke or heart attack or 
sudden cardiac death depending which district is involved (Prathiba et al. 2009). 
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Figure 2– Early phases of atherosclerotic plaque formation. 
Image from Maiolino et al (2013) under Creative Commons Attribution License. 
 
 
 
 
Figure 3 – Scheme of atherothrombosis development. 
Image from Libby et al. (2002). Copyright Clearance Center licence number 439135061396, 17 July 2018 
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3.2 Extracellular matrix: proteoglycans and glycosaminoglycans 
 
As mentioned before, vascular ECM is deeply altered during atherogenesis. 
The ECM is composed of macromolecules network that differs in a cell/tissue-specific 
manner. ECM is not only a scaffold for cell support, but it has also a physiological 
function because by interaction with growth factors and bioactive molecules, it 
regulates the signal transduction and the gene expression (Frantz, Stewart, and Weaver 
2010). Indeed, ECM is a dynamic structure implicated both in tissue organization, 
remodelling and homeostasis and in all cell processes such as proliferation, adhesion, 
migration, differentiation and apoptosis (Yue 2014).  
Fundamentally, ECM is composed by water, proteins and polysaccharides. The major 
components include fibrous protein such as collagen, fibronectin, elastin and laminin 
and proteoglycans (PGs) with their glycosaminoglycans (GAGs) chains. The PGs and 
GAGs fill the interstitial space of tissues left free from fibrous protein forming a well-
organized network that confers tissue hydration (Iozzo and Schaefer 2015).  
In this thesis we focused our attention on syndecans proteoglycans and their GAGs 
chains. 
 
 
3.2.1 Heparan sulfate proteoglycans: syndecans 
 
PG are constituted by a linear core protein with GAGs chains covalently attached. In the 
syndecans proteoglycan, the chains are formed mainly by heparan sulfate (HS).  
Syndecans are a family of four transmembrane molecules that are expressed in a cell-
type-specific manner (Götte 2003): syndecan1 is present during development and in 
adult remains express on endothelial and cancers cells; syndecan2 appears in liver, 
mesenchymal tissue and neuronal cells; syndecan3 is a neuronal type; syndecan4 is 
ubiquitously distributed (Schaefer and Schaefer 2010). The four syndecans are usually 
substituted with HS chains but sometimes isoform 1 and 3 possess additional CS chains 
(Couchman 2010). 
All syndecans have an extracellular N-terminal signal peptide, an ectodomain extending 
out of the cell that bind the GAGs chains, a single hydrophobic transmembrane domain, 
and a short C-terminal cytoplasmic domain composed of two constant domain (C1 and 
C2) and one variable domain (V) (Bernfield et al. 1992) (Figure 4). 
Syndecans are widely express on the cell surface and they act as co-receptors 
promoting the signalling of ligands such as growth factors, extracellular matrix 
components, other cell surface molecules and proteins involved in the regulation of 
blood coagulation (Reiland and Rapraeger 1993). Many these functions depend on HS 
chains interaction with the ligand. 
The extracellular domains anchored to the membrane can be released from the cell 
surface by endogenous proteolytic cleavage that happens in a side close to the plasma 
membrane. This process is known as ectodomain shedding. The shedding permits to 
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liberate the ectodomains as soluble molecules reducing their concentration at the cell 
surface (Fitzgerald et al. 2000). An increase of proteoglycans shedding was found in 
response of inflammatory mediators such as cytokines in various experimental model 
of inflammation (Kolářová et al. 2014). The massive lack of ectodomain damages the 
capacity of syndecans to interact with molecules and lets the cell surface less protect.  
Syndecans are involved in inflammation-relates events: leucocytes-endothelial 
interaction, extravasation, cell migration and proliferation as well as coagulation (Götte 
2003). Moreover, studies conducted in endothelial cells and fibroblasts suggest a role 
of syndecan4 (SDC4) in cell adhesion. It co-localizes with integrins into focal adhesion 
enhanced cell-matrix attachment (Woods and Couchman 1994) and, recently, it seems 
implicated also in cell-cell junction (Gopal et al. 2017). 
 
 
 
 
Figure 4 – Domains structure of syndecans. 
 
 
3.2.2 Heparan sulfate 
 
HS is a linear, negatively charged and sulfated polysaccharide. As all other GAGs 
[chondroitin sulfate (CS), dermatan sulfate (DS), keratan sulfate (KS), heparin (HE) and 
hyaluronan (HA)], HS is composed by a repetition of disaccharides units: uronic acid in 
a form of D-glucoronic acid (GlcA) or L-iduronic acid (IdoA) and amino sugar like D-
galactosamine or D-glucosamine (Kusche-Gullberg and Kjellén 2003).  
HS is mainly present as chain of heparan sulfate proteoglycans (HSPGs) as syndecans. 
To form a mature syndecan is necessary the anchorage and the construction of the 
polysaccharide chain.  
The Figure 5 describes the multistep process of the synthesis of HSPG that starts from 
the adding of tetrasaccharides linkage region to a specific serine residue of core 
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protein. This linkage region is composed by the conserved sequence of xylose–
galactose–galactose–glucuronic acid. The HS biosynthesis continue thanks to 
glycosyltransferases action. Among various members of the exostosin (EXT) family, 
EXT1, EXT2 and EXTL3 are responsible for the chain elongation: EXTL3 catalyzes the 
addition of the first N-acetylglucosamine (GlcNAc), then an alternating adding of 
GlcNAc and GlcA is made by EXT1 and EXT2 (Busse-Wicher, Wicher, and Kusche-
Gullberg 2014). 
Before the chain completion, many modifications occur on the growing polysaccharide. 
The first is the N-deacetylation and N-sulfation performs by NDST1 (N-deacetylase and 
N-sulfotransferase) on residues of GlcNAc that becomes N-sulfo glucosamine (GlcNS). 
This is followed by epimerization of GlcA in IdoA. Some of iduronic acid can be sulfated 
on residue in 2-O position (2S sulfation) and some glucosamine can be sulfated in 6-O 
(6S sulfation) or 3-O (3-sulfation) position (Multhaupt and Couchman 2012).  
 
 
 
 
Figure 5 – Synthesis of HS chain. 
Image under the terms of the Creative Commons Attribution License 
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The HS synthetic machinery is localized between endoplasmic reticulum and Golgi and 
the substrates are UDP-monosaccharides and PAPS (3’-phosphoadenosine 5’-
phosphosulfate) as a source of free sulfate (John M. Whitelock* and Renato V. Iozzo* 
2005). 
The complex mechanism of biosynthesis and modification of HS chains generate a 
variability in N-sulfation levels along the polysaccharides. It produces a region rich in N-
acetylated residue (GlcA and GlcNAc) called NA domain, a region rich in N-sufated 
residue (IdoA and GlcNS derivates) called NS domain and sequences that contain an 
alteration of both NA and NS units. By the distribution of these domains depends the 
binding with the ligands (Jackson, Busch, and Cardin 1991).  
Two types of binding sequence are known: a) sites for fibroblast growth factor 2 (FGF-
2) and FGF receptors that are characterized by high level of N-sulfated residue located 
in a ectodomain portion far from core protein and b) sites for antithrombin binding that 
depend to a NA domain near the protein core (Esko and Selleck 2002). 
It is evident that the content of charged groups in HS chains is important for 
electrostatic interaction with proteins. Interestingly, if more than 80% of N-
acetylglucosamine become N-sulfo glucosamine and more than 70% of uronic acid is 
converted L-iduronic acid, HS become similar to heparin and can acquire anticoagulant 
functions (Schaefer and Schaefer 2010). 
 
 
3.2.3 Hyaluronan 
 
HA is one of the main components of ECM. It is composed by repetitions of D-glucuronic 
acid (Glc-UA) and N-acetyl-D-glucosamine (Glc-NAc) units linked with β1-3 and β1-4 
bound, respectively. In contrast with all other GAGs, it has not sulphated groups and it 
is present as a soluble molecule not bound to PG core proteins. 
HA is produced at the plasma membrane by three HA synthetases: HAS1, HAS2 and 
HAS3. HASs are multipass transmembrane enzymes able to produce and extrude the 
nascent polysaccharide chain by using the UDP sugars present in the cytoplasm: UDP-
GlcUA and UDP-Glc-NAc (Figure 6). Interestingly, HASs presents a double catalytic 
domain and can interact with the two different UDP-sugar substrates (Viola et al. 2015).  
HA production depends not only on UDP-sugar precursor availability, but also on HASs 
regulations. HAS2, that is the mainly responsible for HA synthesis in adult mammal 
tissues, is not only subject to post traditional modifications as phosphorylation, 
ubiquitination and O-GlcNAcylation but its expression is modulated at the genetic and 
epigenetic level by a natural antisense transcript named HAS2-AS1 (Vigetti et al. 2014). 
This genetic control seems not be present for HAS3 that is regulated by the protein 
Rab10 modulating the enzyme transport to the membrane (Deen et al. 2014). HAS1 is 
usually expressed at low level in the adult tissues and it seems to contribute to 
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inflammation and oncogenesis (Rilla et al. 2013)(Nguyen et al. 2017), but the 
information about its regulation is very scanty. 
 
 
 
Figure 6 – Hyaluronan synthesis and structure 
 
 
Since HA is a very hydrated polymer, it controls the water content and the lubrication 
of all tissues that are critical for cell migration and proliferation. Moreover, HA can 
interact with proteins and PGs which are important in the assembly of ECM and 
pericellular glycocalyx. In fact, depending on the extracellular environment HA 
explicates the activity of inflammation mediator and/or modulator of immune 
response (Petrey and de la Motte 2014). In addition, HA is important for tissue repair 
and in wound healing process (Aya and Stern 2014). 
HA is a size-dependent mediator of inflammation. In human tissue, HA can have 
variable molecular weight ranging from 1,4x107 Da (high molecular weight or HMW-
HA) to fragments of 5x103 Da (low molecular weight or LMW-HA) (Moretto et al. 2015). 
In case of inflammation and tissue injury, HA fragments are more present than in 
normal conditions. Generally, LMW-HA is considered a pro-inflammatory molecule 
while HMW-HA an anti-inflammatory polymer (Petrey and de la Motte 2014). 
Moreover, HMW-HA involved in EMC organization because its presence correlates with 
tissue integrity and cell quiescence. On the other hand, HA fragments are produced in 
presence of stress signals (mechanical or oxidative) or through enzymatic degradation 
of HMW-HA by hyaluronidases (Bollyky et al. 2012b). 
Hyaluronidases (HYAL) are responsible for hydrolysis of β 1-4 bounds inside the HA 
molecule. HA degradation happens both on the cell surface and inside the cell: HAYL2 
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on cell membrane digest HA in fragments that can be internalized by interaction with 
CD44 cell receptor and degraded in lysosome by HYAL1 (Stern and Jedrzejas 2006). 
Most of the biological functions attributed to HA are associated with specific HA cell 
receptors. The main HA receptors are: CD44 the ubiquitous receptor, RHAMM that 
mediates cell mobility, HARE the HA receptor for endocytosis and LYVE1 express on 
lymphatics endothelial cells involved in HA tournover (Viola et al. 2015). CD44 is a type 
I transmembrane glycoprotein implicated in cell activation, survival and migration, 
indicating that CD44 is important in the resolution, rather than the propagation of 
inflammation (Bollyky et al. 2012a). 
 
 
3.3 Glycocalyx in atherosclerosis onset 
 
The endothelial glycocalyx is a carbohydrate-rich layer covering the vascular 
endothelium. It is composed by a network of membrane-bound proteoglycans and 
glycoproteins in which hyaluronic acid and soluble molecules, either plasma- or 
endothelium-derived, are incorporated (Figure 7). 
 
 
  
 
Figure 7 – Left: schematic composition of glycocalyx. Right: electron microscopic overview of goat 
capillaries glycocalyx. Modified image from Gouverneur et al. (2006). Copyright Clearance Center licence 
number 4403580245443, 7 Aug 2018 
 
 
Glycocalyx acts as a barrier between blood plasma and the endothelium explaining 
different functions. 
 Glycocalyx regulates the endothelial permeability restricting the entrance of 
certain molecules, repulsing red blood cells from endothelium and inhibiting 
the adhesion of platelets and leukocytes to the vascular wall (Reitsma et al. 
2007). 
 It has a role in mechanotransduction because its components after 
hemodynamic changes traduce the mechanical forces in biochemical signals 
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responsible to endothelial cells responses. One of these reaction involved the 
nitric oxide production able to regulate the vascular tone (Drake-Holland and 
Noble 2012).   
 Since one of the soluble molecules interacting with glycocalyx is the 
extracellular superoxide dismutase (SOD) that is involved in reduction of 
reactive oxygen species (ecROS) (Qin et al. 2008), glycocalyx seems important 
for the endothelial protection against oxidative stress.  
Glycocalyx is continuously subject to a dynamic balance between biosynthesis and 
degradation. Many factors influence its composition and thickness. One of them is the 
alteration of shear stress promoting by local turbulences that can affect the integrity of 
the glycocalyx causing the endothelial denudation (Ballermann et al. 1998). 
Interestingly, recent studies indicate a pathological role of the endothelial glycocalyx in 
atherosclerosis plaque formation where the hydrodynamic force of blood induces the 
remodeling of the major component of glycocalyx including proteoglycans and 
hyaluronan (Zeng 2017). Since the functions of glycocalyx depend on its structure and 
chemically composition, an irregularly arrangement of glycocalyx reduce its endothelial 
vasculo-protective proprieties (Stancu, Toma, and Sima 2012) leading to an impaired 
endothelial permeability and increased recruitment and infiltration of inflammatory 
cell (Zeng 2017). 
In addition, since the flux of lipoprotein into the arterial wall depends of both the 
plasma concentration and the vessel wall permeability(Cancel et al. 2016), an alteration 
in glycocalyx may allow the LDL passage through dysfunctional endothelial layer and 
their accumulation in the sub-endothelium increasing the sensitivity of the vessel wall 
to this pro-atherogenic stimuli (Kolářová et al. 2014). 
 
 
3.4 Nitric oxide influence on vascular cells 
 
In the vascular system, nitric oxide (NO) plays an important role in regulation of vascular 
tone, cardiac contractility and vascular remodelling because it causes vasodilatation 
and inhibits endothelium contracting factor (Matthys and Bult 1997).  
Since NO is released from endothelium, an endothelial damage can induce changes in 
NO levels favouring atherosclerosis.  
In physiological condition, NO is produced from L-arginine by nitric oxide synthase 
(NOS). This process needs the reduced cofactors nicotinamide-adenine-dinucleotide 
phosphate (NADPH), flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), 
and (6R-)5,6,7,8-tetrahydrobiopterin (BH4), and the presence of Ca2+/calmodulin 
(Palmer, Ashton, and Moncada 1988)(Förstermann and Sessa 2012). Three different 
isoforms of NOSs are known: neuronal (nNOS or NOS1), inducible (iNOS or NOS2) and 
endothelial (eNOS or NOS3).  
As potent vasodilatation factor, NO protects from thrombosis by inhibition of platelets 
aggregation and adhesion to vessel lamina. This prevents the release of platelet-
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derived growth factors that stimulate SMC proliferation and its production of matrix 
molecules (Förstermann and Sessa 2012).  
Pro-inflammatory cytokines as TNFα suppress the expression and function of eNOS in 
endothelial cells. The diminished synthesis of NO lead to an increase of reactive 
nitrogen species (RNS) and reactive oxygen species (ROS) which can promote LDL 
oxidation (Picchi et al. 2006) (Xu et al. 2008). Moreover, the lack of NO inhibition on 
SMC promotes cells stimulation and migration to the site of inflammation (Zhang et al. 
2009) (Figure 8). 
 
 
 
Figure 8 – Effect of TNFα on endothelial NO synthesis. 
 
 
3.5 LDL oxidation in atherosclerosis development 
 
LDL can be physiologically found in the bloodstream where they contribute to 
cholesterol transport. They are retained in ECM by the interaction with negative charge 
GAGs and moving to the subendothelium space they can be acetylated and modified 
by oxidation.  
Oxidized LDL (OX-LDL) is one of the factors that contribute to atherosclerosis 
progression. Despite the presence of OX-LDL in the atherosclerosis plaque are 
confirmed by several in vivo studies (Maiolino et al. 2013), it is not clear if the oxidative 
stress is cause or consequence of the atherosclerosis process and which is the site of 
oxidation. Possible localizations are the tunica intima because here lipoproteins 
accumulate or the blood circulation in case of high cholesterol levels accompanied by 
an oxidative stress condition. 
In the atherosclerotic lesion, OX-LDL stimulate monocytes-macrophages, SMC and 
endothelial cells. An oxidative stimulus in endothelial cells increase the expression of 
adhesion molecules, cytokines and pro-inflammatory factors. These conditions attract 
monocytes-macrophages and SMC. SMC from the media migrate into the intima in 
which they proliferate and contribute to neointimal lesions formation. Here they have 
a phenotypical change: 1) they acquire the capacity to phagocytize OX-LDL and, 
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together with macrophages, form foam cells and create the lipid core of the plaque 
(Lao, Zeng, and Xu 2015); 2) they start to secrete an excess of hyaluronan and collagen 
(Viola et al. 2013)(Bennett, Sinha, and Owens 2016), at first modifying the extracellular 
space of intima, and then promoting the formation of fibrous cap over the lipid core. 
Moreover, OX-LDL present in blood flow can induce a hyperactive state in platelets 
promoting local platelets aggregation (Leiva et al. 2015). 
 
 
3.5.1 LDL receptors 
 
LDL can cross the endothelium by two pathways: vesicles and leaky junctions. Vesicles 
take up LDL from extracellular fluid by receptor-mediated endocytosis, whereas leaky 
junctions are associated with endothelial cells in a state of turnover or death 
(apoptosis) (Dabagh, Jalali, and Tarbell 2009). Although LDL are transported mainly by 
transcytosis (Kuzmenko et al. 2004), hypertension induces apoptosis and increases the 
damage of endothelial junctions, promoting LDL transendothelial transport and 
accelerating atherogenesis (Dabagh, Jalali, and Tarbell 2009). 
Many receptors are involved in LDL uptake. LDL receptor (LDLR) is the principal receptor 
involved in native or normal LDL (N-LDL) interaction, while for OX-LDL several scavenger 
receptors have been identified and the Table 2 resumes the principal ones.  
 
 
Scavenger receptor OX-LDL N-LDL 
SR-A I and II + - 
MACRO + - 
SRCL + - 
CD36 + + 
SR-BI + + 
LOX1 + - 
SREC1 + - 
SP-PSOX + - 
 
Table 2 – Native and oxidative LDL as ligand for various scavenger receptors. 
Data from Goyal et al. (2012). 
 
 
Certain scavenger receptors were widely studied for their involvement in 
atherogenesis. 
Lectin-type oxidized LDL receptor 1 or LOX1 mediates the OX-LDL uptake in endothelial 
cells, macrophages, platelets and SMC. Interestingly, OX-LDL internalization by LOX1 in 
SMC is related with HA synthesis increase that influence cell adhesion and migration 
(Viola et al. 2013). Moreover, LOX1 plays an important role in foam cell formation by 
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binding, internalizing and proteolytically degrading OX-LDL. Since LOX1 is present in 
large amounts in atherosclerotic lesion in vivo and it is associated with oxidative 
markers, it reflect the instability of the plaque (Goyal et al. 2012). 
Another receptor was recently discovered in endothelial cells called ALK1. It is involved 
in LDL transcytosis thought endothelium during hypercholesterolemia (Kraehling et al. 
2016). ALK1 direct binds N-LDL in a different site respect LDLR and, after the 
internalization, promotes a non-degradative pathway that permits the passage of 
intact N-LDL particles from blood to vessel wall. Since ALK1 expression is increased in 
human coronary atherosclerotic lesion (Yao et al. 2007), ALK1 may have a role during 
atherogenesis.  
LDLR, LOX1 and ALK1 are the main receptors implicated in LDL (normal or oxidized) 
uptake responsive to the blood cholesterol concentration. 
 
 
3.6 Therapeutic strategies for atherosclerosis 
 
Atherosclerotic vascular disease is the first cause of death in the world and it is 
responsible for the majority of cases of cardiovascular disease (CDV) including coronary 
heart disease, cerebrovascular disease, and peripheral arterial disease (Badimon and 
Vilahur 2012). 
Over the last years it has become clear that atherosclerosis is a multifactorial disease 
in which many processes contribute to lesion development. Atherosclerosis is not only 
a lipid-driven disease, but also several immune and inflammatory mediators have a role 
in the disorder initiation and progression (Weber et al. 2017). 
Despite the various mechanism involved in atherosclerosis, the cholesterol-lipid 
abnormality level is the major modifiable risk factors for atherosclerosis and plasma 
lipoproteins represent the principal target of drug therapies (Jamkhande et al. 2014). 
Within the blood, there are several lipoproteins that each has a different function in 
lipid transportation. The main lipoproteins are: LDL and HDL (high density lipoprotein).  
LDL-cholesterol is called "bad cholesterol" because it is implicated in cholesterol 
transport from liver to extrahepatic tissue and an increase of its plasma concentration 
contribute to LDL accumulation and oxidation in arterial wall promoting the 
atherosclerotic plaque formation. On the other hand, HDL-cholesterol is known as 
“good cholesterol” because it has an important role in reverse cholesterol transport 
moving the excess cholesterol from peripheral tissue to liver. Moreover, HDL can inhibit 
LDL oxidation (Navab et al. 2000) and, in addition, they have anti-atherosclerotic, anti-
inflammatory and endothelial protective functions (Elshourbagy, Meyers, and Abdel-
Meguid 2014). 
Given that high LDL-cholesterol and low HDL-cholesterol levels are atherosclerosis risk 
factors and they are present in established disease, current available strategies for 
treating atherosclerosis aim to lowering LDL plasma concentration, increasing HDL 
plasma concentration and reducing LDL oxidation (Moss and Ramji 2016). 
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List of atherosclerosis therapeutic approaches, summarizing the information given by 
Toth el at. (2018) and Weber et al. (2018). 
 Statins: the inhibition of HMG-CoA reductase, essential for cholesterol 
synthesis, leads to LDL lowering and HDL increase 
 Ezetimibe: the inhibition of NPC1L1 receptor located in luminal surface of 
enterocytes responsible for cholesterol up-take, leads to LDL lowering 
 PCSK9 inhibitors: inhibition of LDLR degradation by PCSK9 to favour LDL uptake 
and decrease of LDL plasma concentration 
 Microsomal transfer proteins (MTP) inhibitors: inhibition of lipoproteins 
synthesis in intestines and liver 
 Oligonucleotide against ApoB-100 (the major component of LDL): inhibition of 
LDL particles synthesis 
 Increase of HDL presence in blood by:  
o cholesterol ester transfer protein CETP inhibitors (CETP transfer 
cholesterol ester from HDL to LDL leading to a reduction of HDL) 
o use of HDL mimetics  
o endogenous stimulation of ApoA-I synthesis (ApoA-I is the main 
component of HDL 
o direct infusion of ApoA-I (ApoA-I Milano) 
 Bempedoic acid: the inhibition of adenosine triphosphate-citrate lyase, 
important for generate cytosolic acetyl-CoA (cholesterol precursor), leads to 
LDL lowering 
 Anti-platelets aggregation therapy: 
o aspirin + clopidogrel  
o new oral anti-coagulants (NOACs) 
 Immunomodulation: inhibition of IL-1beta with monoclonal antibody 
 Anti-inflammatory therapy: antibodies against P-selectin (P-selectin increase 
during atherogenesis and is involved in leukocytes recruitment) 
 Nutraceutical therapy: 
o monacolins such as bergamot or red yeast rice extract: the inhibition 
of HMG-CoA reductase leads to LDL lowering 
o chokeberry flavonoid extract (anthocyanins, polymeric procyanidins 
and phenolic acids): reduces OX-LDL levels and chemokine attractive 
for monocytes 
o spirulina microalga: reduces total cholesterol levels 
o curcumin: anti-oxidant, anti-inflammatory, analgesic 
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3.6.1 Statins: advantages and disadvantages 
 
Statins are the gold standard pharmacotherapy for managing patients with 
dyslipidemia and high risk of CVD such as full-blown atherosclerosis (Rosenson 2004). 
They inhibit the 3-hydroxy-3-methylglutaril coenzyme A (HMG-CoA) reductase which 
plays a central role in the biosynthesis of cholesterol. 
The effect of statins on lipid metabolism drive to a reduction of LDL levels and an 
increase of HDL levels. Moreover, several studies have shown that statins decrease the 
susceptibility of LDL to oxidation influencing the oxidative stress and atherosclerosis 
(Rosenson 2004). Clinical trials with stains reported that they reduce the risk of 
cardiovascular events decreasing mortality incidence (Taylor et al. 2013). 
Despite statins are the first-choice agents, the therapy can be associated with various 
adverse events as myalgia, myotoxicity and new-onset diabetes (Toth et al. 2018). 
Intolerance symptoms appears within the first 3 months of statins therapy and 
sometimes are demonstrable with laboratories analysis that show abnormal levels of 
muscle creatine kinase (Parker et al. 2013) and hepatic transaminase (Stulc et al. 2015). 
Since an elevated number of statin-treated patients (about 20-30%) are statins 
intolerant or do not answer to stains therapy (Mancini et al. 2011) (Arca and Pigna 
2011), new drugs targets are developing to lowering LDL-cholesterol and to control the 
process of atherosclerosis. 
 
 
3.6.2 PCSK9 inhibitors as a novel therapeutic approach 
 
In clinical practice, the main indication for statins intolerance is PCSK9 inhibition 
therapy. PCSK9 (proprotein convertase subtilisin/kexin type 9) is a member of 
proprotein convertase, enzymes that acts as molecular scissors for the tissue-specific 
processing of multiple precursor proteins (Davignon, Dubuc, and Seidah 2010). PCSK9 
is expressed in a limited number of tissues including liver, kidney, cerebellum and small 
intestine (Seidah et al. 2003). The synthesis starts in endoplasmic reticulum and the 
mature PCSK9 is release in the extracellular space where it can interfere with matrix 
components as HSPGs (Gustafsen et al. 2017). 
In adults, liver is the primary organ that products PCSK9 and releases it into the 
circulation (Davignon, Dubuc, and Seidah 2010). The secreted form of PCSK9 can be 
inactivated by cleavage from proprotein convertase (i.e. furin or PC5/6) (Chaudhary et 
al. 2017). 
The best characterized function of PCSK9 relates to the binding to LDLR in hepatocites 
(Schulz, Schlüter, and Laufs 2015) where PCSK9 can regulate LDLR both in an 
extracellular and in intracellular way. Inside the hepatocytes, PCSK9 acts as a chaperone 
because it binds LDLR precursor in the endoplasmic reticulum and regulates the 
expression of mature LDLR by inducing its degradation before receptor transport to the 
membrane (Schulz, Schlüter, and Laufs 2015). While outside the cell PCSK9 binds to the 
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LDLR, they are internalized through clathrin coated vesicle and LDLR is degraded in 
endosomal/lysosomal way (Horton, Cohen, and Hobbs 2007) (Nassoury et al. 2007) 
(Figure 9).  
The bound of PCSK9 to LDLR regulates the plasma concentration of LDL. Generally, LDL 
binds to the LDLR, they are endocytosed and the receptor is recycled to the cell surface 
(Elshourbagy, Meyers, and Abdel-Meguid 2014). This mechanism favours the presence 
of LDLR in membrane that enhance the LDL intake. PCSK9 reduces the levels of LDLR on 
the cell surface and decreases the uptake of circulating LDL (Schulz, Schlüter, and Laufs 
2015). 
A gain-of-function mutation of PCSK9 are associated with familial hypercholesterolemia 
leading to higher levels of LDL-cholesterol and increased risk of cardiovascular disease. 
Moreover, a loss-of-function mutation in enzyme cause hypocholesterolemia. It is clear 
that plasma levels of LDL-cholesterol are closely related to hepatic expression of PCSK9 
and LDLR (Chaudhary et al. 2017).  
 
 
 
 
Figure 9 – PCSK9 and LDLR interaction in hepatocytes 
 
 
In the last decade, a new pharmacological therapy for lowering cholesterol-LDL is 
proposed antagonizing PCSK9. Inhibition of PCSK9 results in an increased LDLR 
presence on cell surface capable to increase the up-take of LDL-cholesterol (Weber et 
al. 2017) (Figure 10). 
The main approaches used to reduce PCSK9 synthesis and PCSK9/LDLR interaction 
consist of a) inhibition of PCSK9 expression using anti-sense oligonucleotides and short 
interference RNA, b) disrupting PCSK9 binding with LDLR using a mimic peptide and c) 
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inhibition of PCSK9 activity on LDLR using neutralizing antibodies (Davignon, Dubuc, 
and Seidah 2010) (X. L. Lin et al. 2018). 
The most advanced approach is the administration of fully human monoclonal IgG 
antibodies against PCSK9 (Glerup et al. 2017). Evolocumab and alirocumab have been 
approved in USA and Europe in 2015. They show positive results by decreasing LDL-
cholesterol of about 50-60% and by increasing HDL (more than 4%) and recent meta-
analysis calculated a 50% reduction of cardiovascular events (Stulc et al. 2015) (Solanki, 
Bhatt, and Johnston 2018).  
In addition to lowering LDL-cholesterol, evolocumab in combination with statins 
demonstrated regression of atherosclerotic lesions in terms of the percent atheroma 
volume and total atheroma volume (Solanki, Bhatt, and Johnston 2018).  
 
 
 
 
Figure 10 – LDL plasmatic concentration is regulated by PCSK9 and LDLR levels 
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4 – AIM OF THE WORK 
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Atherosclerosis is a chronic inflammatory disease where an endothelial dysfunction and 
the LDL accumulation in vascular wall lead to ECM modification and atherosclerotic 
plaque formation. 
Given that glycocalyx alterations can cause changes in endothelial permeability and this 
may promote LDL passage inside vessel wall, the first aim of this study was to clarify 
the role of hyaluronan and syndecans, two of the major component of glycocalyx, in 
endothelial cells after inflammatory stimulus. 
After a validation of the model consisting in HUVEC treated with TNFα, it was evaluated 
the expression of enzymes involved in hyaluronan synthesis and its presence in 
pericellular coat. In addition, protein core and GAGs chains composition of syndecans 
were studied in order to evaluate: a) the core protein expression and its implication in 
endothelial permeability, b) the quality of HS chains and their influence on platelets 
stimulation. 
Another part of the work is dedicated to PCSK9, a novel therapeutic target for 
cholesterol lowering and atherosclerosis. 
Although PCSK9 is mainly synthetized by the liver, such protein is also present in blood. 
Therefore, the second aim of my work is to study whether PCSK9 influence the 
expression of receptors involved in LDL intake in vascular cells and in which way the 
extracellular matrix is implicated in that process. 
PCSK9 expression and production was assessed in HUVEC and hAoSMC after 
stimulation with LDL (normal and oxidized) to clarify PCSK9 behaviour in extrahepatic 
cells. Subsequently, HUVEC and hAoSMC stimulated with PCSK9 were used to evaluate 
the effect of PCSK9 on expression of some LDL receptors and on hyaluronan 
metabolism. 
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5 - MATERIALS AND METHODS 
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5.1 Cell cultures 
Human umbilical vein endothelial cells (HUVEC) obtained from Gibco, were grown for 
4-8 passages in Medium 200 culture medium (Gibco) supplemented with 2% fetal 
bovine serum. The cultures were maintained in an atmosphere of humidified 95% air, 
5% CO2 at 37 °C. Twenty-four hours before treatments, subconfluent HUVEC were 
cultured in DMEM with 0.5% fetal bovine serum. The medium was then changed to 
Medium 200 with 0.1 µg/ml of TNF-alfa (Sino Biological Inc.) or with 20 µg/ml of normal 
or oxidized LDL or with 80-100 ng/ml of PSCK9 (R&D Systems) and incubated for 24 or 
48 hours. 
Human aortic smooth muscle cells (hAoSMCs) obtained from Gibco were cultured at 
37°C in an atmosphere of 5% CO2 relative humidity between passages 4-8 in Medum 
231 culture medium (Gibco). After 24h starvation in DMEM with 0.2% fetal bovine 
serum, cells were treated with 20 µg/ml of normal or oxidized LDL or with 80-100 ng/ml 
of PSCK9 for 24 hours. 
 
5.2 Quantitative RT-PCR  
Total RNA samples were extracted from untreated or treated cells with Absolutely RNA 
Microprep Kit (Agilent Thechologies). cDNAs were generated by using the High Capacity 
cDNA synthesis kit (Applied Biosystems) and were amplified on an Abi Prism 7000 
instrument (Applied Biosystems) using the Taqman Universal PCR Master Mix (Applied 
Biosystems) following the manufacturer’s instructions. The following human TaqMan 
gene expression assays were used: HAS2 (Hs00193435_m1), HAS3 (Hs00193436_m1), 
NOS1 (Hs00167223_m1), NOS2 (Hs01075529_m1), NOS3 (Hs01574659_m1), SYND1 
(Hs00174579_m1), SYND2 (Hs00299807_m1), SYND3 (Hs00206320_m1), SYND4 
(Hs00161617_m1), NDST1 (Hs00155454_m1), EXT1 (Hs00609162_m1), EXT2 
(Hs00181158_m1) and β-actin (Hs99999903_m1). For some genes the expression was 
measured using SYBR Green Master Mix (Applied Biosystems). In this case we used the 
following primers: ALK1 designed on the basis of NM_000020.2 sequence (forward nt 
981-1001; 5’-CGAGGGATGAACAGTCCTGG-3’ and reverse nt 1057-1078; 5’-
GTCATGTCTGAGGCGATGAAG-3’), LOX1 designed on the basis of NM_001172632.1 
sequence (forward nt 948-969; 5’-GCCTGGCACCTTTATGTCAAC-3’ and reverse nt 990-
1016; 5’-CTTGGGACAAGCTAGGTGAAATAATA-3’), PCSK9 designed on the basis of 
NM_174936.3 sequence (forward nt 1534-1550; 5’-ACGTGGCTGGATTGCA-3’ and 
reverse nt 1593-1616; 5’-AAGTGGATCAGTCTCTGCCTCAA-3’), LDLR designed on the 
basis of NM_000527.4 sequence (forward nt 492-510; 5’-AAGGCTGTCCCCCCAAGA-3’ 
and reverse nt 548-567; 5’-CGAACTGCCGAGAGATGCA-3’), and housekeeping β-Actin 
designed on the basis of NM_001101.4 sequence (forward nt 1172-1195; 5’-
TCAAGATCATTGCTCCTCCTGAG-3’ and reverse nt 1238-1259; 5’-
ACATCTGCTGGAAGGTGGACA-3’). The relative quantification of gene expression levels 
was determined by comparing 2-ΔΔCt (Viola et al. 2013). 
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5.3 Western blotting 
RIPA buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% TRITON X-100, 0.5% sodium 
deoxycholate, 0.1% SDS) containing Protease Inhibitor Cocktail (Sigma) was used to 
prepare cell lysates. Proteins were quantified, separated by 12% sodium dodecyl 
sulphate polyacrylamide gel electrophoresis and transferred to nitrocellulose 
membrane. After incubation in blocking solution (5% BSA in 1X Tris-Buffered Saline 
Tween-20), membrane was incubated overnight with primary antibody at 4°C. 
Antibodies used were rabbit polyclonal antibody against Syndecan4 (ABT157, Merck 
Millipore, dilution 1:250) and goat polyclonal antibody against β-actin (#J1805, Santa 
Cruz Biotechnology, dilution 1:1000). The membrane was washed with 1x TBS-T and 
incubated 1 hour with secondary antibody. Bands visualization was carried out by the 
chemiluminescence system LiteAblot TURBO (Euro Clone). The relative intensities of 
the protein bands were analysed with ImageJ software. β actin levels were used as 
controls for protein loading. 
 
5.4 LDL isolation and oxidation 
Native LDL was isolated from plasma of normolipidemic healthy volunteers kindly 
provided by the “Ospedale di Circolo” of Varese. After ultracentrifugation at 4°C, LDL 
were collected, freed of EDTA by gel filtration using PD-10 column (GE Healtcare) and 
concentrated with Centriprep Centrifugal Filters (10 KDa, Merck). LDL was oxidized with 
1mM CuSO4 overnight at 37°C. At the end of incubation time, the effective oxidation of 
LDL was monitored by recording the increase of absorbance at 234nm comparted with 
normal non-oxidized LDL (Albertini et al. 1999) (Viola et al. 2013). 
 
5.5 ELISA for PCSK9 quantification 
Conditioned media from treated cells were collected and used for the protein 
quantification of PCSK9 by the Quantikine ELISA kit (R&D Systems) following the 
protocol provided by the manufacturer. 
 
5.6 Cell transfection 
HUVEC were transfected with siRNA against syndecans4 (S12639, Ambion) using a 
nucleofector apparatus (Amaxa) and the Amaxa HUVEC Nucleofactor kit (Lonza) 
following manufacturer’s instructions.  Briefly, 5x105 cells were resuspended in 100 µl 
HUVEC Nucleofector solution and transfected with 40nM siRNA against syndecans4. 
Cells were treated 24 hours after the transfection. The control siRNA used was Silencer 
Negative Control siRNA #1 (AM4611, Ambion). The syndecans4 silencing efficiency was 
determined by qRT-PCR. 
 
5.7 Cell viability assay 
HUVEC metabolic activity was evaluated with the MTT assay. Cells were seeded at a 
density of 6x103 cells/well in a 96 well plate. The following day, HUVEC were treated 
with 0.1 µg/ml of TNFα. After 4, 16, 24 or 48 hours, the cells were washed with PBS and 
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MTT solution (50 μl of 5 mg/ml) was added to each well for 4 hours al 37°C. 
Subsequently, the medium was removed and dimethyl sulfoxide (Sigma-Aldrich) was 
added (200 µl/well) to solubilize the formazan crystals. Optical density was measured 
at 570 nm with Tecan microplate reader (Thermo Scientific). 
 
5.8 Wound healing assay 
HUVECs seeded in 6-weel plates were cultured until confluence. Three parallel 
scratches were introduced to the HUVEC monolayer with a 200 µl sterile pipette tip. 
Cells were washed to remove debris and incubated in fresh medium with or without 
TNFα. Images from three different scratch areas in each culture well were obtained 
using Olimpus IX51 microscope after 2, 4, 6 and 8 hours. 
 
5.9 Red blood cell exclusion assay 
Pericellular area (coat) around HUVEC was visualized using a particle exclusion assay 
involving human erythrocytes fixed with formaldehyde. Cells were seeded at a density 
of 6x103 cells/well in 12-well plate and treated or untreated (control) with TNFα. After 
24 hours, 500 μl of a suspension of fixed and washed human erythrocytes (15x106 
erythrocytes/ml) was added to the cells and allowed to settle for 20 minutes at 37°C. 
Images of pericellular coat were obtained using phase contrast microscope Olimpus 
IX51. The dependence of the pericellular matrix on HA was shown by treating the 
cultures with 2 U/ml of HA-specific Hyaluronate Lyase from Streptomyces 
hyalurolyticus (Sigma) in medium for 1 hours at 37°C before visualization with the 
particle exclusion assay. Representative cells were photographed at a magnification of 
×40. ImageJ software was used to quantify area delimited by red blood cells and the 
area delimited by the cell membrane to give a coat-to-cell ratio (Vigetti et al. 2009). 
 
5.10 Transwell permeability assay 
FITC labelled dextrans were used as the representative of hydrophilic molecules to 
measure the permeability of endothelial cell monolayer (Lal et al. 2001) (Simoneau, 
Houle, and Huot 2012). HUVEC were plated in the upper part of a Transwell filter (0.4 
µm, 6.5 mm diameter, Corning) at a density of 8x103 cell per well and were cultured 
until the formation of a tight monolayer checked with microscope. Cells were treated 
with TNFα (0.1 µg/ml) and FITC-dextran (Mw~250000 Sigma) was added to the top 
chamber of the Transwell for a final concentration of 1 mg/ml. The culture medium in 
the upper and in the lower chamber was collected 24 hours post-treatment and 
fluorescence was measured by fluorimeter (Tecan, Thermo Scientific) with an 
excitation wavelength of 490 nm and an emission wavelength of 520 nm. To evaluate 
the FITC-dextran passage thought cells monolayer, we calculated the total fluorescence 
of each well adding upper fluorescence value and lower fluorescence value. Total 
fluorescence was used to find the percentage of fluorescence of the lower chamber. 
Lower percentage value of control has been set as 1 to normalize the others. 
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5.11 Glycosaminoglycans determinations 
Glycosaminoglycan released into the culture medium or binding on cells membrane 
were extracted using the protocol of Viola et al. (Viola et al. 2008). Briefly, after the 
stimulation of samples, conditioned media were collected as well as trypsin 
supernatants after cells harvesting (membrane GAGs extraction). Samples were 
subjected to digestion with proteinase K (20 U/ml, Finnzymes) and precipitation with 
ethanol (9:1/ethanol:water) in order to recover GAG in the pellets. HE/HS disaccharides 
were obtained digesting the GAG with a mix of heparinases I–II–III (form F. heparinum, 
Seikagaku) and AMAC (Sigma) derivatization. HE/HS disaccharides were used for HPLC 
relative quantification and characterization. As standards we used a mix of non-sulfated 
(0S), mono-sulfated (6S, NS, S2), di-sulfated (S1) and tri-sulfated (Tri-S) AMAC-derived 
HE/HS disaccharides at the concentration of 5 nmol (Seikagaku). While, HS GAGs were 
purified through a digestion with chondroitinase ABC (from Proteus vulgaris, 
Seikagaku) for 5 hours at 37°C. After the uronic acid quantification, HS were used for 
platelets adhesion and spreading assay. 
 
5.12 Glucuronic acid quantification 
HS GAGs content (membrane and medium) was measured by using uronic acid 
quantification following the van den Hoogen et al. method (van den Hoogen et al. 
1998). Brefily, to each well of a 96 plate was applied 40 µl of HS sample and 200 µl of 
concentrated sulfuric acid (80% w/w) was added. The plate was placed in incubator for 
1 hour at 80°C and, after cooling to room temperature, the background absorbance of 
samples was measured at 540nm on a microplate reader (Tecan, Thermo Scientific). 
Then, 40 µl of 3-hydroxybiphenyl solution (100 µl of 3-hydroxybiphenyl (Fluka) in 
DMSO, 100 mg/ml mixed with 4.9 ml 80% (v/v) sulfuric acid) was added. After an 
overnight incubation the absorbance of the pink-colored samples was read again at 
540nm. A commercial D-Glucuronic acid (Sigma) was included as standard series. The 
background absorbance was subtracted from the second reading and the uronic acid 
content was interpolated from the corresponding reference curve. 
 
5.13 Platelet-rich Plasma (PRP) preparation 
As described in Posner et al. (Posner et al. 2015), human blood was drawn from healthy 
volunteers by median cubital vein puncture under local ethics committee approval. 
Sodium citrate was used as anticoagulant (0.5% w/v for platelet isolation, 0.1% w/v for 
whole blood experiments). PRP was separated from whole blood by centrifugation (200 
g, 15 min), and platelets were separated from PRP by a second centrifugation step (400 
g, 10 min), in the presence of prostaglandin E1 (PGE1, 40 ng/ml) and indomethacin (10 
M). Washed platelets were then resuspended in a modified Tyrode’s-HEPES buffer (10 
mM HEPES, 145 mM NaCl, 2.9 mM KCl, 1 mM MgCl2, 5 mM glucose, pH 7.3) at a density 
of 4x108 /ml. 
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5.14 Platelet adhesion and spreading assay 
Following Canobbio et al. (Canobbio et al. 2016) protocol, glass coverslips were coated 
overnight at room temperature with 100 μg/ml fibrinogen, 0.32 µg HS GAGs from 
membrane or medium and then blocked with 1% BSA for 2 hours at room temperature. 
Washed platelets (0.5 ml; 4×107 cells/ml) were added to dishes coated with fibrinogen 
and GAGs in the presence of 1 mM CaCl2. No-adherent cells were discharged, and 
adherent platelets were fixed, permeabilized with Triton X-100, and actin filaments 
were stained by TRITC-conjugated phalloidin. Platelets were viewed on a fluorescence 
microscope (Olympus BX51), and digital images (400×) were acquired. The number of 
adherent cells was determined using the ImageJ Version 1.42 software. 
 
5.15 Data analysis 
Data are presented as mean ± S.D. Statistical significance was determined using 
unpaired Student’s t test. Statistical significance was established at P < 0.05 for *, P < 
0.01 for ** and P < 0.001 for ***. 
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6 – RESULTS 
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6.1 HUVEC treated with TNFα as in vitro model of endothelial inflammation 
 
Atherosclerosis is a chronic inflammation of arterial vessel wall. One of the 
atherosclerosis triggering factor is the endothelial dysfunction in response to 
inflammation stimuli. Since the development of atherosclerosis is coupled to dramatic 
alteration of extracellular matrix components, we used HUVEC treated with TNFα as a 
model of endothelium inflammation to clarify the role of glycocalyx components as HA 
and HS PGs in the onset of atherosclerosis. 
The experiments were carried out by using HUVEC left untreated (control) or treated 
with TNFα 0.1 µg/ml for 24 hours and ECM composition studied in conditioned media 
or in the cells extracts. To validate our in vitro model, nitric oxide synthases (NOSs) 
expression levels were analysed after the cytokine stimulation. Nitric oxide (NO) is 
important to maintain normal vascular functions and endothelial integrity. As expected, 
the endothelial isoform NOS3 was the most expressed form in HUVEC (Figure 11A). 
Moreover, the expression levels of NOS3 and NOS1 were significant decreased after 
TNFα stimulation while NOS2 showed a non-significant tendency to decrease (Figure 
11B). These data agree with the literature where in vitro studies confirm the defect in 
the NO production in isolated atherosclerotic blood vessels (Matthys and Bult 1997).  
Since a reduction in NO synthesis and/or enzymatic activity may contribute to the 
initiation and progression of atherosclerosis (Napoli and Ignarro 2018), we can consider 
HUVEC treated with TNFα a good in vitro model of endothelial inflammation of 
atherosclerosis early stage. 
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Figure 11 - Effect of TNFα on NO synthesis enzymes in HUVEC. A, relative expression of NOSs (neuronal 
NOS1, inducible NOS2 and endothelial NOS3) in HUVEC. B, NOSs expression in HUVEC untreated (control) 
and treated with TNFα (0.1 µg/ml) for 24 hours. Data are mean ± S.D. of three independent experiment, 
*** p<0.001. 
 
  
N
O
S1
N
O
S2
N
O
S3
0
50
100
150
800
1000
1200
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
NOS1
Control TNF
0.0
0.5
1.0
1.5
***
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
NOS2
Control TNF
0.0
0.5
1.0
1.5
2.0
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
NOS3
Control TNF
0.0
0.5
1.0
1.5
***
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
A 
B 
43 
 
 
 
6.2 TNFα regulates HA synthesis enzymes and increases the HA presence in the 
endothelial coat area 
 
Hyaluronan (HA) is the principal component of extracellular matrix and it is produced 
by HAS1, HAS2 and HAS3. HA can have a pro or anti-inflammatory role depending on 
its molecular mass. Since HA molecular mass can depend on which HASs is expressed, 
we measured the level of the HASs in cells control. In untreated HUVEC cells, HAS3 
mRNA was the most abundant whereas HAS1 messenger was not detected (Figure 
12A). Interestingly, after TNFα stimulation, HAS2 and HAS3 increased and decreased 
expression, respectively (Figure 12B). 
HASs are transmembrane enzymes able to extrude out of the cell the nascent 
polysaccharides chain as well as able to retain the nascent HA bond to the plasma 
membrane. Therefore, HA is not only present in the conditioned medium, but also 
present around endothelial cells surface as a component of glycocalyx. To evaluate the 
pericellular space (i.e. glycocalyx) as well as amount of HA, we performed the particle 
exclusion assay. The pericellular space was significant increased after TNFα stimulation. 
Moreover, the coat disappeared after specific HA lyase (Hyaluronidase) treatment and 
remain increased when HUVEC were treated with both TNFα and Hyaluronidase 
inactivated with high temperature. These results indicated that the modulation of HASs 
expression by TNFα altered the HA presence in the endothelial pericoat. 
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Figure 12 - Effect of TNFα on Hyaluronan synthesis in HUVEC. A, HASs expression profile in HUVEC. B, 
relative expression of HAS2 and HAS3 in HUVEC untreated (control) and treated with TNFα (0.1 µg/ml) for 
24 hours. Data are mean ± S.D. of four independent experiment, *** p<0.001. C, particle exclusion assay 
performed on HUVEC control and under TNFα stimulation (0.1 µg/ml) for 24 hours. To clarify the HA 
composition of the pericellular matrix, we digested HA with 2 U/ml of Hyaluronate Lyase from 
Streptomyces hyalurolyticus (HYAL) before addition of erythrocytes. Original magnification 40 x. Values 
represent the measure of single cell pericellular area (control n=70, TNFα n=118, TNFα+HYAL n=21 and 
TNFα+HYAL heat inactivated n=19) and the red bars are the mean of three independent experiments, *** 
p<0.001 and **p<0.01 
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6.3 HUVEC vitality and migration are not influenced by TNFα 
 
In the vascular system HA is important to maintain the vascular homeostasis and it has 
a crucial role in glycocalyx as well as in the regulation of angiogenesis during the normal 
wound healing (Slevin et al. 2007). Moreover, its viscoelastic propriety is important for 
the vascular remodelling during atherosclerosis development.  
To verify if the increase of HA presence in HUVEC coat after TNFα stimulation influence 
the vitality and migration of endothelial cells, we performed an MTT assay and a wound 
healing assay. The data in Figures 13 and 14 proved that endothelial metabolic activity 
and migration were not affected by TNFα treatment. 
 
 
  
 
     
Figure 14 - Wound healing assay of HUVEC. The assay was conducted in HUVEC treated with TNFα (0.1 
µg/ml) and control cells. Representative photographs were taken at 0 h and 8 h post-scratch (× 40) and the 
scratch closure was quantified at 0, 2, 4, 6 and 8 hours post-wound by measuring the remaining unmigrated 
area using ImageJ. Values represent mean ± S.D. (n=3). 
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Figure 13 - MTT vitality assay. HUVEC 
were treated with TNFα (0.1 µg/ml) and 
after 6, 16, 24, and 48 hours cell viability 
was assessed by MTT assay. Values 
represent mean ± S.D. (n=2). 
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6.4 SDC4 increases after TNFα stimulation in HUVEC 
 
Syndecans are a family of four transmembrane proteoglycans acting as co-receptors 
interacting with different molecules including growth factors, matrix components and 
cytokines that are present in glycocalyx (Götte 2003). To test their involvement in 
endothelial inflammation, we evaluated the expression of the different isoforms (SDC1, 
SDC2, SDC3, SDC4) in HUVEC treated or untreated (control) with TNFα for 24 and 48 
hours.  
Despite SDC3 and SDC4 were the most expressed isoform in HUVEC, only SDC4 was 
upregulated by TNFα and the increase of mRNA levels remained high also after 48 hours 
of treatment. Data were confirmed by western blot analysis (Figures 15 A, B and C). 
SDC4 seemed the major isoform implicated in inflammation response of endothelial 
cells. 
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Figure 15 - TNFα influence on syndecans core protein. A, Syndecans expression profile in HUVEC. B, 
expression of syndecan isoforms in HUVEC control and after 24 and 48 hours TNFα stimulation (0.1 µg/ml). 
Values represent mean ± S.D. (n=3), ** p<0.01. C, western blot analysis of SDC4 protein in HUVEC 
untreated and treated 24 hours with TNFα (0.1 µg/ml). Bar chart represents normalized mean ± S.D. of 
two independent experiment and the figure is a representative SDS-PAGE. 
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6.5 SDC4 silencing influences the endothelial permeability in HUVEC 
 
Atherosclerosis onset is driven by a massive flow of LDL that pass though the damaged 
endothelium and lead to a LDL accumulation in the sub-endothelium; in fact, is well 
known that one of the major atherosclerosis trigger factor is the accumulation of LDL 
(normal and modified) in the tunica intima (Leiva et al. 2015). To test whether the 
endothelial permeability is altered under inflammatory condition, we cultured HUVEC 
in a transwell system over a permeable membrane (0.4 µm pore size) and we measured 
FITC-dextran passage through the endothelial monolayer. As reported in Figure 16A, 
the presence of the HUVEC layer (control) over the membrane leaded to the 
fluorescence decreasing in the lower compartment in comparison with membrane 
alone (no cells), showing that dextran passage was prevented by cells covering the 
membrane pore. When HUVEC were treated with TNFα there was a significative 
reduction of FITC-dextran passage compared with the control. 
Since SDC4 seemed to have an important role in cell adhesion, we investigated the 
effect of SDC4 on endothelial permeability. We transfected the cells with siRNA against 
SDC4 and the SDC4 silencing increased the FITC-dextran passage compared with 
siControl (siRNA scrambled) (Figure 16B) indicating a role of SDC4 in endothelial 
permeability. 
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Figure 16 - Transwell permeability assay. A, scheme of FITC-dextran flow through HUVEC monolayer. B, 
the experiment was performed using HUVEC control and treated with TNFα (0.1 µg/ml) for 24 hours or 
transfected with a scrambled siRNA (siControl) or with siRNA against SDC4 (siSDC4). Confluent cells were 
treated (or not) with TNFα (0.1 µg/ml) and 1 mg/ml of dextran conjugated with FITC was added to the 
upper chamber. After 24 hours the medium in the lower chamber was collected and FITC fluorescence was 
measured. Data in the left graph are mean ± S.D. of two experiments conducted in duplicate, * p<0.05 and 
** p<0.01, while in the right graph they are preliminary data of a single experiment. 
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6.6 TNFα alters syndecans HS chains in HUVEC: both enzymes of chain biosynthesis 
and N-sulfated levels are affected 
 
As mentioned in the introduction, syndecans are composed of core protein and lateral 
chains formed by GAGs present in the ectodomain. Since the main GAG is HS and many 
critics functions are played by HS, we measured HS content in conditioned medium and 
in plasma membrane compartment of HUVEC treated and untreated (control) with 
TNFα. We have distinguished medium GAG from membrane ones because syndecan 
ectodomain can be present in association with plasmatic membrane as whole 
transmembrane protein or in the medium as soluble molecule after protein shedding 
(Couchman 2010). Although there were no changes in the amount of HS (Figure 17), 
we analysed the expression levels of the main enzymes involved in HS chains 
biosynthesis; in particular EXT1 and EXT2 that are important for chain elongation and 
NDST1 for chain maturation. TNFα increased the expression levels of all chain 
biosynthetic enzymes take in consideration (Figure 18). 
Importantly, NDST1 catalyses the N-deacetylation and N-sulfation of N-
acetylglucosamine (GlcNAc) that become N-sulfo glucosamine (GlcNS). Since NDST1 
transcription was altered in inflammation response (see Figure 18), we analysed the 
composition in HS/HE disaccharides of HS extracted from medium and membrane of 
HUVEC, both control and TNFα treated, using HPLC analysis. As shown in Table 3, TNFα 
altered the level of GlcNAc sulfation both in membrane and in the medium HS/HE 
disaccharides: di-sulfation (S1) on GlcNAc and on C6 of GlcNS, and mono-sulfation level 
(NS) on GlcNAc were increased. These increases of GlcNAc sulfation levels after TNFα 
stimulation seemed to agree with the increase of NDTS1 expression. On the other hand, 
there was a reduction of mono-sulfation level (S6) on C6 of GlcNAc in the GAGs 
membrane and of non-sulfation (0S) in GAGs medium. 
TNFα treatment drived to an alteration in sulfation level of HS both in membrane and 
in medium. It seemed that TNFα affected not only the protein but all the syndecan 
molecules, HS chains included. 
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Figure 17 – GAGs quantification. HS GAGs extracted from conditioned medium and plasma membrane of 
HUVEC untreated and treated 24 hours with TNFα (0.1 µg/ml), were used to measure the concentration 
of glucuronic acid as detector of HS quantity. Data are mean ± S.D. of three independents experiments. 
 
 
 
 
Figure 18 - Expression levels of enzymes involved in HS chains biosynthesis. EXT1 and EXT2 are involved 
in chains elongation while NDST1 acts in chains modification and maturation. Using RT-PCR analysis the 
transcription levels of EXT1, EXT2 and NDST1 were examined in HUVEC control and stimulated with TNFα 
(0.1 µg/ml) for 24 hours. Values represent mean ± S.D. (n=3), *** p<0,001. 
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Table 3 - HPLC analysis of main HS/HE disaccharides. A, scheme of main modifications of HS disaccharides. 
B, GAGs were isolated from plasma membrane and from culture medium of HUVEC control and TNFα 
treated (0.1 µg/ml for 24 hours). To obtain HS/HE disaccharides we digested GAGs with heparinases. After 
AMAC derivatization, the disaccharides were analyzed by means of HPLC. Data are express as % area of HS 
/ % area total. Values are mean ± SD of three independent experiment, ** p<0.01. 
  
A 
B 
53 
 
6.7 Alteration in N-sulfation levels of syndecans HS chains affects platelets 
stimulation 
 
Sulfated GAGs chains present in the glycocalyx provide negative charge for the 
endothelial surface layer and contribute to repulsion of platelets and leukocytes to the 
vascular wall in normal condition (Kolářová et al. 2014). Since syndecan GAGs chains 
interact with circulating blood cells and we found altered N-sulfated levels in HS from 
medium and membrane, we wanted to test the behaviour of platelets in presence of 
HS GAGs. In collaboration with and Dr. Jessica Canino (PhD student of University of 
Pavia supervised by Dr. Ilaria Canobbio from Department of Biology and 
Biotechnology), we performed a platelets adhesion and spreading assay. We used 
fibrinogen as positive control (100% of platelets adhesion and spread) and intact 
extracted HS GAGs (long chains) from HUVEC membrane and medium with or without 
TNFα treatment. HSs extracted were used to coat a glass slide and isolated platelets 
were added. Adherent platelets were visualized in immunofluorescence after staining 
of actin filaments with phalloidin-TRITC as described in methods. As shown in Figures 
19 A and B, HSs extracted from the medium of HUVEC TNFα stimulated leaded to a 
tendency to increase in platelets adhesion and a significant decrease in spreading 
index. While membrane HSs did not influence platelets conduct. 
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Figure 19 - Platelets adhesion and spreading assays. HS purified from plasma membrane or from culture 
medium of HUVEC control or TNFα treated (0.1 µg/ml for 24 hours) were used for platelets assay. Platelets 
were let to adhere on glass coverslips coated with 0.32µg of HS GAGs, as described in methods. A, 
representative images at 400× magnification of adherent platelets are reported. B, quantification of 
platelets adhesion and spreading is reported as % of fibrinogen used as positive control for these assays. 
Values represent mean ± S.D. of five independent experiments, ** p<0.01. Data are made in collaboration 
with Dr. Ilaria Canobbio and Dr. Jessica Canino of Pavia University. 
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6.8 LDL influence LDLR both in HUVEC and hAoSMC, but PCSK9 is expressed and 
influenced by LDL only in hAoSMC 
 
Despite the exact causes of atherosclerosis are still unknown, high levels of cholesterol 
in blood is associated with an elevated risk of cardiovascular diseases. Cholesterol in 
LDL or in OX-LDL, seems to be involved in atherosclerosis plaque formation (Rafieian-
Kopaei et al. 2014). For lowering cholesterol levels (total and LDL-associated), statins 
are the first-line choice for patients with established disease (Rosenson 2004). 
However, many patients are intolerant or do not answer to stains therapy (Chaudhary 
et al. 2017) (Arca and Pigna 2011). In the last decade, a new pharmacological therapy 
is proposed antagonizing PCSK9. In hepatocyte, PCSK9 reduces LDL intake from 
circulation by enhancing LDLR degradation and preventing LDLR recycling to the cell 
surface (X.-L. Lin et al. 2018). Therefore, PCSK9 inhibition decreases the cholesterol-LDL 
levels in blood. 
Although PCSK9 performs its principal action on liver, the tissue target of 
atherosclerosis process is the vessel wall. Therefore, we investigated the possible role 
of PCSK9 in endothelial cells and smooth muscle cells.  
To develop a system as similar as possible to atherosclerosis situation characterized by 
high level of cholesterol, we treated HUVEC and hAoSMC with N-LDL and OX-LDL for 24 
hours to assess if PCSK9 can be produced locally in vascular cells. The expression of 
LDLR and PCSK9 was evaluated by RT-PCR, and PCSK9 concentration in conditioned 
medium was quantified by using an ELISA commercial kit. 
Results indicated that both HUVEC and hAoSMC replied to LDL (N and OX) 
downregulating the LDLR (Figures 20 and 21 A and B), adopting a feedback negative 
mechanism.  
While PCSK9 was not transcript in HUVEC treated and untreated and it was not present 
in HUVEC conditioned medium, PCSK9 expression decreased after LDL (both N and OX) 
stimulation in hAoSMC (Figure 21A). Moreover, OX-LDL leaded a diminished release of 
PCSK9 in hAoSMC medium (Figure 21B). Interestingly, PCSK9 and LDLR show the same 
regulation after LDL stimulation in smooth muscle cells. 
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Figure 21 – LDL influence on LDLR expression and PCSK9 production in hAoSMC. A, after 24 hours of LDL 
(N and OX, 20 µg/ml) treatment, hAoSMC mRNA was used for quantify LDLR and PCSK9 expression. Values 
represent mean ± S.D. of three independent experiments, ** p<0.01 and * p<0.05. B, PSCK9 quantification 
using ELISA commercial kit. Values represent mean ± S.D. (n=3), * p<0.05. 
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Figure 20 – LDL regulation on LDLR expression in 
HUVEC. RT-PCR analysis of LDLR in HUVEC control and 
treated with N and OX LDL (20 µg/ml) for 24 hours. 
Values represent mean ± S.D. of three independent 
experiments, *** p<0.001 and * p<0.05. 
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6.9 Effect of PCSK9 stimulation on LDL receptors in vascular cells 
 
Although PCSK9 inhibitory effect on LDLR in liver is well known, its role in vascular cell 
remains cryptic. As PCSK9 is produced primary from liver and it is present in blood as 
circulating factor, we tested if PCSK9 has an influence on the main LDL receptors in 
vascular cell. 
HUVEC and hAoSMC were treated with two different concentration of PCSK9: 80 ng/ml 
and 100 ng/ml. These values were respectively quantified in healthy patients and in 
hypercholesterolemic subjects by Dubuc et al (Dubuc et al. 2010). Since LDL can enter 
the cells by different mechanisms, we focused our attention on LDLR, the receptors for 
N-LDL, LOX1 the scavenger receptor for OX-LDL and ALK1 that is implicated in LDL 
transcytosis in endothelial cells. 
In HUVEC, LDLR and LOX1 transcription tended to increase, while LOX1 showed a 
dramatic reduction after stimulation with both PCSK9 concentrations (Figure 22A). In 
addition, to evaluate the regulation of LDLR by PCSK9 in a hypercholesterolemic 
situation, HUVEC were co-treated with PCSK9 and N-LDL. LDLR transcription after N-
LDL treatment was downregulated (confirmed as shown before) and it remained low 
after co-stimulation with PCSK9 and N-LDL (Figure 22B). It suggests a primary role of N-
LDL to LDLR regulation despite of PCSK9.  
LDLR and ALK1 mRNA levels were not affected by PCSK9 stimulation in hAoSMC, while 
LOX1 tended to decrease with the lower concentration of PCSK9 (Figure 23). 
These data sudgest that in vascular cells, both endothelial and smooth muscle, PCSK9 
has more influence on LOX1 scavenger receptor in comparison with LDLR that is 
regulated by LDL.  
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Figure 22 – PCSK9 effect on LDL receptors in HUVEC. A, expression of LDLR, LOX1 and ALK1 in HUVEC 
control and after 24 hours of PCSK9 treatment (80 and 100 ng/ml). B, LDLR transcription levels in hAoSMC 
control and co-treated with PCSK9 (both concentrations) and N-LDL (20 µg/ml) for 24 hours. Values 
represent mean ± S.D. (n=3), * p<0.05. 
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Figure 23 – PCSK9 influence on LDL receptors in hAoSMC. Expression of LDLR, LOX1 and ALK1 in hAoSMC 
control and after 24 hours of PCSK9 treatment (80 and 100 ng/ml). Values represent mean ± S.D. (n=3), * 
p<0.05. 
 
   
  
LDLR
C
on
tr
ol
P
C
S
K
9 
80
 n
g/
m
l
P
C
S
K
9 
10
0 
ng
/m
l
0.0
0.5
1.0
1.5
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
LOX1
C
on
tr
ol
P
C
S
K
9 
80
 n
g/
m
l
P
C
S
K
9 
10
0 
ng
/m
l
0.0
0.5
1.0
1.5
2.0
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
ALK1
C
on
tr
ol
P
C
S
K
9 
80
 n
g/
m
l
P
C
S
K
9 
10
0 
ng
/m
l
0.0
0.5
1.0
1.5
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
60 
 
6.10 HA synthesis is sensible to PCSK9 treatment in HUVEC and hAoSMC  
 
Since OX-LDL accumulated in the vascular intima can adhere to extracellular matrix 
components, we evaluated the effect of PCSK9 on HA biosynthesis in vascular cells. 
HUVEC and hAoSMC were treated with both PCSK9 concentrations and HAS2, HAS3 and 
CD44 expression was quantified with RT-PCR analysis. 
HAS2 and CD44 transcription tended to decrease but without significance in HUVEC, 
while HAS3 was significantly reduced by PCSK9 treatment (both concentrations) (Figure 
24A). HAS3 was downregulated also in hAoSMC after PCSK9 stimulation, while HAS2 
mRNA levels were decreased after stimulation with the higher concentration of PCSK9 
(Figure 24B). Moreover, the expression of CD44 decreased in relation with HASs 
decrease in hAoSMC. These data suggest a protective role of PCSK9 in vascular wall 
decreasing the expression of HA synthesis enzyme and its specific receptor. 
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Figure 24 – HA metabolism in vascular cells after PCSK9 stimulation. Expression of HAS2, HAS3 and CD44 
in HUVEC (A) and hAoSMC (B) control and treated with PCSK9 (80 and 100 ng/ml) for 24 hours. Values 
represent mean ± S.D. (n=3), *** p<0.001, ** p<0.01 and * p<0.05. 
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7 – DISCUSSION 
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In this study we investigated the role of hyaluronan and syndecans in HUVEC after TNFα 
stimulus in order to understand in vitro their impact on the endothelial inflammation, 
one of starting point of atherogenesis. In addition to this, we examined the action of 
PCSK9 in endothelial and smooth muscle cells to expand knowledge about its role in 
vascular district. 
 
After TNFα treatment, our model showed changes in hyaluronan metabolism including 
the decrease of HAS3 expression, the increase of HAS2 and the augment of HA presence 
in pericelllular space. We used particle exclusion assay to measure HA only in the 
pericellular coat and not in the medium in order to evaluate HA in the glycocalyx in vivo. 
HA is a crucial regulator of endothelial inflammation. Since HAS3 is associated with 
LMW-HA synthesis that has pro-inflammatory proprieties, the decrease of HAS3 seems 
to have an endothelial protective role. In fact, the inhibition of HAS3-dependent 
synthesis of HA decrease the inflammation in atherosclerotic plaque in has3/Apoe 
deficient mice (Homann et al. 2018). On the other hand, the increase of HAS2 related 
with a HA-rich pericellular space suggests its pro-inflammatory role promoting the 
interaction between endothelial cell and leukocytes or platelets that express CD44, the 
principal HA receptor. In agreement with that, Vigetti et al demonstrated that HA 
synthesis due to HAS2 up-regulation promotes monocytes adhesion of endothelial cells 
via NF-kB pathway (Vigetti et al. 2010).  
Further, despite HAS2 produces the anti-inflammatory HMW-HA, it can be subjected to 
fragmentation by digestive enzymes as hyaluronidases (HYALs) or oxidative stress. 
HYALs not only from the pro-inflammatory HA oligosaccharides but also, they degrade 
HA on the apical surface of endothelial cells and lead to a change in the glycocalyx layer 
(Kong et al. 2016). In fact, in vivo study demonstrate that a systemic inhibition of HA 
synthesis by 4-MU interferes with the protective function of the endothelial glycocalyx, 
facilitating inflammation and progression of atherosclerosis (Nagy et al. 2010). HMW-
HA can be cleaved into fragments also by platelets that up-regulate leukocyte 
production of chemokines and cytokines (Sadowitz et al. 2012). 
Another glycocalyx component studied were syndecans which were influenced by TNFα 
both in core protein expression and in N-sulfation levels of HS chains.  
Despite SDC4 and SDC3 were the most represented core protein isoform in HUVEC, 
only SDC4 showed an altered expression. Its up-regulation due by TNFα seems to be 
related to NF-kB (Okuyama et al. 2013) that is implicated in inflammatory responses. 
An increase of SDC4 core protein can activate PKCα pathway involved in antithrombin-
III modulation and endothelial prostacyclin release (Götte 2003) which are important 
factors for the regulation of platelets aggregation and vascular tone. Since syndecans 
are subjected to shedding, an increase of soluble ectodomain of SDC4 can favour HS 
chains interaction with a multitude cell types as leucocytes and platelets as well as with 
soluble factors as FGF-2. The interaction of HS with FGF-2 can promote the repair of 
endothelial damage (Melrose 2016). 
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Moreover, we demonstrated that the increase expression of SDC4 affects the 
endothelial cell permeability. Since SDC4 is present in adherent junctions (Gopal et al. 
2017) (Cavalheiro et al. 2017), we speculate that the decrease of FITC-dextran passage 
through HUVEC monolayer can be involved in the compensatory mechanism of 
endothelial cell in order to prevent the LDL passage to the subendothelium.  
In order to examine the importance of the levels of N-sulfated residues in syndecans 
interaction, we found an increase of N-sulfation on the GlcNS-6S residue that was 
directly related with the increase of NDST1 expression, the specific enzyme that 
catalyzes this modification. Moreover, the N-sulfated alteration involved all HS residues 
analysed. Change in HS quality (not in total amount of HS but in N-sulfation) induced 
platelets spreading reduction that is correlated with anti-coagulant proprieties. 
Alternatively, platelets express CD44 and can interact with HA present in the glycocalyx. 
Therefore, after TNFα treatment, a HA-rich pericellular space increases the platelets 
recruitment favouring platelets aggregation. 
As represented in the Figure 25, an inflammatory stimulus as TNFα can altered ECM 
characteristics (i.e. HS N-sulfation and HA) which alter the endothelial glycocalyx 
composition modulating immune cell recruitment (monocytes and platelets) and 
affecting the endothelial permeability. These aspects highlight the contribution of 
inflammation to regulate the endothelial behaviour that has a critical role in 
atherosclerosis development. 
 
 
 
 
Figure 25 – Mechanisms of action proposed for hyaluronan and syndecans, the major endothelial 
glycocalyx components, in response to an inflammatory stimulus in the early phase of atherosclerosis 
onset. HA-rich glycocalyx can stimulate the monocytes recruitment and favour an inflammation reaction, 
while syndecan4 localized in adherent junction can close the space between cells and prevent the LDL 
passage. Moreover, an alteration of N-sulfation levels of HS chains seems have an anti-coagulant action in 
confront to platelets stimulation. 
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Another aspect we have focused on is PCSK9. Although the role of PCSK9 in liver is well 
known, no information is available on PCSK9 role in vascular district. In fact, PCSK9 is 
known to be released in the bloodstream and can differently affect cholesterol 
metabolism in several tissues (Gustafsen et al. 2017). Our results indicated that PCSK9 
has similar but not equal action on LDL receptors and HASs expression in endothelial 
cells and in SMC.  
We demonstrated that PCSK9 is not only express and secreted by liver but also by SMC. 
Moreover, in these cells PCSK9 production is regulated by both N-LDL and OX-LDL. Since 
OX-LDL induce apoptosis increasing Bax and decreasing Blc-2 (Kataoka et al. 2001), 
PCSK9 in SMC can be implicated in cell death and this could be an important target for 
preventing and delaying the atherosclerosis in the early stages (Li et al. 2017). On the 
other hand, endothelial cells do not express PCSK9 neither in N-LDL nor in OX-LDL. Our 
data are in agreement with several studies demonstrating that PCSK9 expression in 
endothelial cells is less than in smooth muscle cells. However, in another study PCSK9 
can be regulated in concentration-dependent manner by LPS (Ding et al. 2015). 
It is known that healthy patient and hypercholesterolemic subjects have a PCSK9 
circulating concentration of 80 and 100 ng/ml, respectively (Dubuc et al. 2010). 
Therefore, we treated vascular cells with such amounts of PCSK9 to verify a dose 
dependent effect. 
LDL receptors did not show alteration in their expression in both cells lines. 
Interestingly, LOX1, the main OX-LDL scavenger receptor in endothelial cells, was 
dramatically reduced after PCSK9 treatments. Since LDLR seems to be regulated mainly 
by N-LDL in HUVEC, it could be that PCSK9 acts not on N-LDL receptors but only on 
scavenger receptors. Consequently, the decrease of LOX1 expression could inhibit the 
uptake of the pro-inflammatory factor OX-LDL that could also cause an oxidative stress 
and damage the endothelial layer. Interestingly, also HA synthesis is known to be 
regulated by OX-LDL as well as (R)-hydrocholesterol in vascular cells (Viola et al. 2013).  
As HA has a critical role in atherosclerosis onset (Viola et al. 2013) ,we verify whether 
PCSK9 modulates HA metabolism. In HUVEC we found that HAS3 decreases after PCSK9 
treatments. This regulation could lead to diminished immune cells recruitment 
correlating to an anti-inflammatory response. This finding is intriguing because it will 
permit to specifically study the critical role of HAS3 in vascular endothelial cells.  
On the other hand, in SMC we found a reduction of HAS2 and HAS3 after PCSK9 
treatments. As in SMC HA is primary involved in proliferation and migration (Cuff et al. 
2001), the effect of PCSK9 of these cells could be positive reducing HASs expression 
that could correlate with an increase vascular protection.  
To further confirm this new protective role of PCSK9 in vessels, we studied CD44. This 
molecule is known to be a critical HA receptor required for atherosclerosis 
development mediating immune cells infiltrated in subendothelium, SMC 
differentiation and signalling (Cuff et al. 2001). After PCSK9 treatments, we clearly 
showed a CD44 decrement in SMC highlighting that PCSK9 could impair different 
mechanisms involved in atherosclerosis onset.  
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Another important mechanism that could be involved with HA metabolism is platelets 
stimulation. In fact, the observed reduction of HASs expression could diminish the HA 
content in the glycocalyx preventing platelets adhesion, activation and eventually 
aggregation reducing thrombus formation. 
Very recently, it has been discovered that PCSK9 can be interact with HS in N-sulfation 
rich domain (Gustafsen et al. 2017). Since we found the TNFα alters HS chemical 
composition in N-sulfation, we can speculate that HS with an increase of such 
modification could bind PCSK9 and leave LDLR free to interact with LDL (Figure 26). 
Therefore, HS proteoglycans could be use as biological PCSK9 inhibitor and, 
consequently, as a new therapeutic approach. This point is crucial because in recent 
years there is an increasing interest in glycobiology. As HS and other GAGs are able to 
interact with different molecules and are involved in practically every area of biology 
(i.e. coagulation process, helping cells to communicate or to recognize pathogens, 
cancer metastasis, ecc), they are emerging as important factors in the most 
programmes of biological drug. 
In conclusion, despite PCSK9 inhibition has a pivotal role in LDL-cholesterol lowering in 
hepatocytes, we find that the PCSK9 in vascular district could have protective effects 
inhibiting critical mechanism regulating LDL scavenger receptors expression and HA 
metabolic enzymes that are involved in vessel thickening. 
 
 
 
 
Figure 26- Proposed attractive action of HS proteoglycans with high levels of N-sulfation on PCSK9. 
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